Qynapse to Present Clinical Results of QyScore(R) for Alzheimer's Disease and Multiple Sclerosis at the Congress of the European Academy of Neurology
AsiaNet 90060
Qynapse to Present Clinical Results of QyScore(R) for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology
BOSTON, June 15, 2021 /PRNewswire=KYODO JBN/ --
QYNAPSE Inc., a medical technology company commercializing the most advanced
artificial intelligence neuroimaging platform, today announced it will present
clinical data on QyScore(R) for Alzheimer's disease and multiple sclerosis at
the 7th Congress of the European Academy of Neurology (EAN), which is being
held virtually on June 19 - 22, 2021.
Logo - https://mma.prnewswire.com/media/1333172/Qynapse_Logo.jpg
The QyScore(R) [ https://www.qynapse.com/qyscore-software/ ] platform, which
is both FDA-cleared and CE-marked, provides automated quantification of a broad
portfolio of neurodegenerative and neuroinflammatory markers and advanced
visualization capabilities that are accessible by physicians. QyScore(R)
integrates an automated comparison of patient results with a large normative
dataset of healthy controls, supporting faster clinical decisions, timely
diagnosis and precise monitoring of Alzheimer's disease, multiple sclerosis,
Parkinson's disease and other neurological disorders.
At the EAN Congress, Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give
an ePresentation titled, "Diagnostic Accuracy of QyScore(R) MRI Markers in the
Clinical Spectrum of Alzheimer's Disease" on June 20, 2021, at 6:05 a.m. ET /
12:05 CEST. Additionally, Philippe Tran, R&D Scientist at Qynapse, will give an
ePoster titled, "Brain Volumes Alterations in Multiple Sclerosis Patients:
Comparison to QyScore(R) Normative Data" on June 20, 2021, at 1:30 p.m. ET /
19:30 CEST.
"We are pleased to present new data on QyScore(R) at the EAN Congress, which
are showing its clinical value for the diagnosis and assessment of disease
progression for multiple sclerosis, mild cognitive impairment and Alzheimer's
disease patients," said Olivier Courreges, CEO of Qynapse. "For Alzheimer's
disease, in light of the recent approval by the FDA of ADUHELM (Aducanumab), we
are excited to work on future developments of our neuroimaging solution, to
support the treatment initiation and the monitoring of its efficacy and safety.
We look forward to sharing and discussing our latest advances with experts in
the field throughout the EAN event."
About QYNAPSE Inc.:
QYNAPSE is a medical technology company that develops and markets solutions
maximizing the potential of quantitative imaging and artificial intelligence to
optimize diagnosis, prognosis and monitoring of patients with neurological
diseases. QYNAPSE is marketing its QyScore(R) software for the automated
quantification of imaging markers for clinical routine and clinical trials
worldwide and launching QyPredict(R) , an AI prediction technology for better
targeted patient selection in clinical trials.
QYNAPSE is headquartered in France, in the United States and in Canada.
www.qynapse.com
Yse Salle de Chou (QYNAPSE) / ysalledechou@qynapse.com / +33-6-95-12-33-32
Source: QYNAPSE
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。